All patients underwent MP-MRI on a 3.0-T MRI (Achieva, Philips Healthcare) with 4 sequences–triplanar T2-weighted, dynamic contrast-enhanced, diffusion-weighted imaging, and MR spectroscopy–according to previously published protocols.17 (link) Images were acquired with a 16-channel surface coil (SENSE, Philips Healthcare) and an endorectal coil (BPX-30, Medrad) in most cases or just a surface coil in a few patients. These MP-MRI studies underwent blinded, centralized radiologic evaluation, and lesions were assigned suspicion scores of low, moderate, or high. These scores are based on findings on each MP-MRI sequence using previously described criteria13 and have been associated with both the presence of prostate cancer and tumor grade6 (link),18 (link) (eMethods and eTable 1 in the Supplement). The now standardized PI-RADS criteria19 (link) were not in use at our center during the time frame of this study. Two highly experienced genitourinary radiologists (B.T. and P.L.C.) with 8 and 14 years of experience interpreting prostate MP-MRI performed independent review and formed consensus reads of all studies in this series.